(nonlethal temporary incapacitation formulation and novel solvent system)
RN 7360-38-5 HCAPLUS
CN Hexanoic acid, 2-ethyl-, 1,2,3-propanetriyl ester (9CI) (CA INDEX NAME)



L58 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:501816 HCAPLUS
DOCUMENT NUMBER: 133:109988
TITLE: Transdermal antipruritic preparations with improved bioavailability
INVENTOR(S): Ohara, Kunio; Tanaka, Nobuyuki
PATENT ASSIGNEE(S): Health Science Center Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000204046	A2	20000725	JP 1999-4433	19990111
JP 3022541	B1	20000321		
PRIORITY APPLN. INFO.:			JP 1999-4433	19990111

AB The prepns. are obtained by mixing antipruritic agents and bases containing fatty acid polyalc. esters, oily substances, lower alcs., and H2O. The prepns. are not sticky or slimy. An aqueous liquid containing **nonylic acid vanillylamide**, sucrose palmitate, sucrose stearate, **glyceryl tri(2-ethylhexanoate)**, glycerin, EtOH, and hinokitiol showed long-lasting antipruritic effect in humans without causing adverse effects.
IT **2444-46-4**, **Nonylic acid vanillylamide**
7360-38-5, **Glyceryl tri(2-ethylhexanoate)**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal antipruritic prepns. with improved bioavailability)
RN 2444-46-4 HCAPLUS
CN Nonanamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)